Arteparon

09/01/1982 - "By the use of a biochemically induced animal model of osteoarthrosis we studied the chondroprotective properties and anti-arthritic potency of glycosaminoglycanpolysulfate (GAGPS; Arteparon) in-vivo. "
01/01/1977 - "[Use of arteparon in the treatment of primary osteoarthrosis deformans]."
12/01/1972 - "[Use of Arteparon in osteoarthrosis of the knee joint. "
10/01/1978 - "[Evaluation of Arteparon therapy for large joint arthroses (author's transl)]."
07/01/1977 - "[Glycosaminoglycanpolysulfate (GAGPS, Arteparon) for basic therapy of arthrosis. "

06/01/1992 - "This patient had never received heparin, but had repeatedly been treated with Arteparon for degenerative joint disease. "
10/01/1981 - "Arteparon, a polysulfated glycosaminoglycan, has been used in Europe for two decades in the treatment of degeneration joint disease and is currently being tested in this country. "
07/01/1977 - "Investigations using 3H-Arteparon (3H-glycosaminoglycan polysulfate, 3H-GAGPS) showed that in humans with degenerative joint disease an intramuscular administration of 125 mg GAGPS (0.5 ml Arteparon forte) produces GAGPS concentrations within the joint, which in a biochemical assay inhibit cartilage degrading lysosomal enzymes. "
12/15/1991 - "Polysulphated glycosaminoglycans (Adequan, Arteparon) the new treatment for degenerative joint disease in dogs."
06/01/1992 - "By crossreactivity studies we have demonstrated that sera of patients with HAT type II activate platelets in vitro not only after the addition of heparin but also after addition of a chemically polysulphated chondroitin-like substance, Arteparon, used for treatment of degenerative joint disease. "

09/16/1982 - "The indications to include the patients into our study were: arthrosis and other cartilage disorders that had been diagnosed prior to onset of therapy by means of either X-ray, surgery, arthrography etc. Therapeutic results were measured by the parameters: subsidence of pain, recession of edema, improved joint motion, etc. Arteparon, applied intra-articularly, was well tolerated; local irritation, and swelling of the treated joints were reported in only 4.7% of the treated cases; the therapeutic overall result was good. "

09/16/1982 - "The indications to include the patients into our study were: arthrosis and other cartilage disorders that had been diagnosed prior to onset of therapy by means of either X-ray, surgery, arthrography etc. Therapeutic results were measured by the parameters: subsidence of pain, recession of edema, improved joint motion, etc. Arteparon, applied intra-articularly, was well tolerated; local irritation, and swelling of the treated joints were reported in only 4.7% of the treated cases; the therapeutic overall result was good. "

05/01/1985 - "Drug treatment of these rats with twice weekly subcutaneous doses of 1.0 mg, 2.0 mg or 5.0 mg glycosaminoglycan polysulphate = GAGPS (Arteparon) per kg body weight caused a pronounced and in many cases highly significant reduction of the intensity of experimental osteoarthrosis within the first 9 weeks. "